Up to 36 months durability of functional cure in response to bepirovirsen therapy in B-Clear On-NA responders: Results from the B-Sure study

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
Barcelona, Spain
May 27-30, 2026


Up to 36 months durability of functional cure in response to bepirovirsen therapy in B-Clear On-NA responders: Results from the B-Sure study

	EASL 2026 May 26-30 Barcelona EASL: Clinically meaningful rates of functional cure in virologically suppressed patients with chronic hepatitis B infection treated with bepirovirsen: B-Well Phase 3 Trials - (05/28/26) EASL: Phase 3 Results of Bepirovirsen HBV - (05/28/26) EASL 2026 May 26-30 Barcelona Seng-Gee Lim1,